Physician profile
Dylan Lauri Steen
NPI 1073711826
$90,552.71
in general payments reported to CMS, 2019-2025
10 companies · $373 in 2025
The $373 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $25K · 2020: $30K · 2021: $24K · 2022: $8,597 · 2023: $140 · 2024: $2,146 · 2025: $373.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,803 · Food and Beverage: $824 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,802.50 |
| Food and Beverage | $824.40 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $88,140.50 | 2019-2024 | |
| Novo Nordisk INC | $1,000.34 | 2019-2024 | Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $381.48 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $363.07 | 2022-2025 | |
| Amgen INC. | $297.21 | 2024-2025 | Repatha |
| Cleerly, INC. | $155.89 | 2025 | Cleerly Labs, Cleerly Ischemia |
| Cardiovascular Systems INC. | $94.21 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $73.13 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $33.42 | 2023 | Xarelto |
| Esperion Therapeutics, INC. | $13.46 | 2024 | Nexletol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dylan Steen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.